OncLive Staff

Selcodebart improved hemoglobin levels and transfusion independence across 3 anemia cohorts in myelofibrosis, regardless of concomitant JAK inhibitor use.

Faculty convened at an OncLive Scientific Interchange and Workshop to discuss HER2-mutant NSCLC testing, treatment selection, and sequencing strategies.

OS in the LIVERATION trial of namodenoson in advanced HCC appeared longer than anticipated, prompting consideration of an earlier interim analysis.

Micvotabart pelidotin produced a 36% confirmed ORR and a 6.2-month median PFS in pretreated recurrent/metastatic head and neck squamous cell carcinoma.

Dabogratinib led to a high rate of responses FGFR3-altered low-grade intermediate-risk non–muscle-invasive bladder cancer.

Durvalumab plus tarlatamab significantly improved OS and PFS vs durvalumab alone as maintenance in extensive-stage SCLC, per topline phase 3 data.

Signatera assay ctDNA testing showed stronger prognostic and predictive value than PET/CT imaging across lymphomas.

Arlocabtagene autoleucel met the primary end point of overall response rate in the registrational phase 2 QUINTESSENTIAL trial.

Patients with triple-class–exposed relapsed/refractory multiple myeloma reported improvements in pain, fatigue, and functioning during up to 2 years of linvoseltamab.

Pegylated G-CSF produced rates of successful CD34-positive cell collection and safety comparable to daily G-CSF in healthy allogeneic transplant donors.

The top 5 OncLive TV videos of the week cover insights in essential thrombocythemia, CML, pancreatic cancer, myelofibrosis, and chronic neutropenia.

Alternating VR-CAP and rituximab plus cytarabine with continuous acalabrutinib produced deep responses and high MRD negativity in untreated MCL.

The FDA approved camizestrant for ESR1-mutated breast cancer, cleared ropeginterferon alfa-2b for essential thrombocythemia, and more.

Dana Chase, MD, discusses why B7-H4 has emerged as a promising antibody-drug conjugate target in ovarian and endometrial cancer.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Daraxonrasib produced a 42% overall response rate and 16.0-month median OS in previously treated RAS-mutant NSCLC in a phase 1/2 trial.

Ivonescimab significantly improved OS vs pembrolizumab at a prespecified interim analysis of the HARMONi-2 trial in first-line PD-L1–positive NSCLC.

Etentamig improved ORR and PFS vs standard therapies in triple-class exposed relapsed/refractory multiple myeloma.

A pharmacokinetic sub-study found that TAMP-mediated gemcitabine reduced systemic drug exposure in patients with locally advanced pancreatic cancer.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.

Faculty convened at an OncLive Scientific Interchange and Workshop to discuss optimizing first-line treatment selection and second-line sequencing in EGFR-mutated NSCLC.

MT027, an off-the-shelf B7-H3–directed CAR T-cell therapy, earned FDA fast track designation for recurrent glioblastoma.

T-DXd plus pertuzumab was approved in the European Union as first-line treatment for unresectable or metastatic HER2-positive breast cancer.

The zanidatamab-plus-chemotherapy arm met its overall survival end point at the second interim analysis of the phase 3 HERIZON-GEA-01 trial.

The combination met its primary end point in the phase 3 SANOVO trial, though full efficacy and safety data have not yet been reported.

The supplemental new drug application was submitted under the accelerated approval pathway with a request for priority review.

The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.

The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.

Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.